GSK (GSK): news on Wednesday 14 October 2026

The 20 stories

Each headline's own score, strongest first. Links go to the publisher.

• +9.2 GSK Announces Drug Manufacturing Expansion In Pennsylvania Pharmaceutical Online
  Manufacturing expansion in Pennsylvania signals investment and growth.
• +8.3 GSK Sets 2027 Construction Start for $800M Pennsylvania Buildout - Engineering News-Record Engineering News-Record
  $800M Pennsylvania buildout confirms major investment plans.
• +5.0 How AI Drug Discovery Will Impact GSK (LSE:GSK) Investors Simply Wall Street
  AI drug discovery framed as potential opportunity for investors.
• −5.0 JPMorgan keeps GSK stock Underweight at GBp 1,700.00 target - ad-hoc-news.de ad-hoc-news.de
  JPMorgan stays Underweight with a target below current price.
• +5.0 GSK (LSE: GSK) Shares Trade At A P/E Discount To Peers Despite 51.8% Five-Year Gain Foreign Policy Journal
  Shares at P/E discount to peers after strong five-year gain.
• +4.2 Insider share acquisitions support GSK stock as upward price move persists Traders Union
  Insider buying and continued upward share price move.
• +3.3 GSK partners with the medical community to raise awareness and stay updated on scientific advancements regarding severe asthma in Vietnam. Vietnam.vn
  Community engagement on severe asthma in Vietnam; mildly positive.
• −2.5 RBC holds on GSK ahead of third-quarter results as HIV cliff looms Proactive Investors UK
  RBC holds, warns of looming HIV cliff.
• −1.7 Is GSK (LSE:GSK) Resetting Its Pipeline After Dropping Camlipixant And Backing Lung Cancer? Kalkine Media
  Dropping camlipixant is a setback, offset by lung cancer backing.
• +1.7 GSK declares RUSD 0.4265938970 dividend per unit for BRG1SKBDR 008, payable Oct. 15 VZ VermögensZentrum
  Routine dividend declaration on depositary receipts.
• +1.7 GSK Q3 results expected in line as vaccine weakness offset by HIV and respiratory drug strength Pluang
  In-line Q3 expected; vaccine weakness offset by HIV and respiratory.
• +1.7 GSK Executives Increase Holdings Through Dividend Reinvestment TipRanks
  Executives increasing holdings via dividend reinvestment, routine.
• +1.3 Dividend reinvestment brings GSK (NYSE: GSK) CEO Luke Miels 23.331 ordinary shares. Stock Titan
  CEO dividend reinvestment, small routine share acquisition.
• +1.3 Dividend reinvestment gives Iain Whyte 1,182 GSK (GSK) shares at £17.5904 each. Stock Titan
  Routine insider share acquisition through dividend reinvestment.
• +1.3 GSK PDMRs Purchase Shares Through Dividend Reinvestment on October 8, 2026 Kalkine Media
  Routine director share purchases via dividend reinvestment.
• +0.8 GSK third quarter likely to be in line as RBC sees vaccine headwinds offset by HIV strength Proactive financial news
  In-line quarter expected with vaccine headwinds offset by HIV.
• +0.8 GSK discloses CEO shareholding and GSK stock costs EUR 21.20 - ad-hoc-news.de ad-hoc-news.de
  Routine CEO shareholding disclosure.
• +0.8 GSK reports 3-share CEO purchase; stock pre-market at EUR 21.06 - ad-hoc-news.de ad-hoc-news.de
  Small CEO share purchase; routine.
• +0.3 GSK Likely to Deliver In-Line Q3, RBC Says Yahoo Finance
  Analyst expects in-line quarter; neutral.
• 0.0 GSK plc : RBC gives a Neutral rating www.marketscreener.com
  RBC Neutral rating maintained.